// App-Quantinova.ai

2505 : Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).

Researchers

Presenter

  • Haeseong Park

Principal Investigators

  • Johanna C. Bendell

  • Wells A. Messersmith

  • Drew W. Rasco

  • Johann S. De Bono

  • John H. Strickler

  • Lei Zhou

  • Laura L Carter

  • Jean-Marie Bruey

  • Jack Li

  • Kartik Raghupathi

  • Jakob Dupont

  • Marya F. Chaney

  • Wungki Park

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • University of Colorado Denver School of Medicine, Aurora, CO

  • START San Antonio, San Antonio, TX

  • The ICR and Royal Marsden, London, United Kingdom

  • Duke University College of Medicine, Durham, NC

  • Gossamer Bio, Inc.,San Diego, CA,USA

  • Merck & Co., Inc., Kenilworth, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04060342

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved